Union Korea Pharm
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Union Korea Pharm makes prescription medicines, including antibiotics, musculoskeletal, cardiovascular, and digestive drugs, supplied to hospitals and pharmacies in South Korea and exported to markets across the Middle East, Southeast Asia, and Latin America.
Listed on KOSDAQ, South Korea's small-cap board, the company serves both domestic healthcare providers and overseas buyers. Its business runs across three streams: domestic prescription-drug sales, international exports of finished medicines, and contract manufacturing (CMO), producing finished drugs on behalf of other pharmaceutical companies that lack certain production facilities.
Summary is AI-generated and may contain errors · figures from DART filings
The company also outsources production of dosage forms it does not manufacture in-house to third-party firms, a mutual arrangement it describes as strategically complementing its own product lineup.
Union Korea Pharm in five facts
What does Union Korea Pharm do?
Union Korea Pharm makes prescription medicines, including antibiotics, musculoskeletal, cardiovascular, and digestive drugs, supplied to hospitals and pharmacies in South Korea and exported to markets across the Middle East, Southeast Asia, and Latin America.
Where is Union Korea Pharm listed and in which sector?
Union Korea Pharm (Korean name: 한국유니온제약) trades under KRX code 080720 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Health Care sector, Pharmaceuticals.
How large is Union Korea Pharm?
Its market capitalisation was US$145.2M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Union Korea Pharm's latest annual revenue and operating profit?
For fiscal year 2025, Union Korea Pharm reported revenue of US$27.5M, an operating loss of US$13M and a net loss of US$23.3M, per its annual report on DART (data retrieved from DART on 2026-10-02). Revenue was down 29.1% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-10-02
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Material event report (capital reduction)Oct 21
- Material event report (rights offering)Capital raise · Oct 21
- [Amended] Half-year report (2026.06)Oct 12
- DisclosureOct 8
- Results of extraordinary shareholders' meetingOct 8
- Proxy solicitation reference documentSep 23
- Notice of general shareholders' meetingSep 23
- [Amended] Resolution to convene a general shareholders' meetingSep 16
- Resolution to convene a general shareholders' meeting (extraordinary meeting)Sep 1
- Shareholder register closure / record date setSep 1
- Other market noticeAug 31
- DisclosureAug 31
- [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$21.6M, about 15.6% of its market value.
Capital raise · Aug 19 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$21.2M, about 15.6% of its market value.
Capital raise · Aug 11 - [Amended] Material event report (rights offering)
Union Korea Pharm amended its May 2026 rights-offering report, pushing the new-share listing date from 2026-08-18 to 2026-08-28; the underlying filing covers a third-party-allotted capital increase of 51,660,308 common shares at US$0.35 each as part of a court-approved debt-to-equity conversion under its rehabilitation plan, which also changes the company's largest shareholder.
Capital raise · Aug 11 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$20.8M, about 15.6% of its market value.
Capital raise · Jul 29 - [Amended] Material event report (rights offering)
Union Korea Pharm amends its May 18, 2026 rights-offering report to push the expected listing date for the 51,660,308 new common shares from August 5, 2026 to August 18, 2026 due to processing delays at the Korea Securities Depository; the shares are issued at US$0.35 par/issue price in a third-party placement that converts rehabilitation claims into equity under a court-approved rehabilitation plan.
Capital raise · Jul 29 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$20.3M, about 15.6% of its market value.
Capital raise · Jul 22 - [Amended] Material event report (rights offering)
Union Korea Pharm Co., Ltd. amended its May 18, 2026 rights offering disclosure to change the expected new-share listing date from July 29, 2026 to August 5, 2026, due to administrative delay with the Korea Securities Depository; the underlying filing covers a third-party allotment of 51,660,308 common shares at US$0.34 per share under a court-approved rehabilitation plan.
Capital raise · Jul 22 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$20.2M, about 15.6% of its market value.
Capital raise · Jul 14 - [Amended] Material event report (rights offering)
Union Korea Pharm Co., Ltd. amended its May 18, 2026 report on a third-party-placement rights offering of 51,660,308 common shares (issue price US$0.34/share) issued through debt-to-equity conversion under its court-approved rehabilitation plan, changing only the expected new-share listing date from July 22, 2026 to July 29, 2026 due to delays in settlement-agency procedures.
Capital raise · Jul 14 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$20M, about 15.6% of its market value.
Capital raise · Jul 8 - [Amended] Material event report (rights offering)
Union Korea Pharm Co., Ltd. amended its May 18, 2026 rights offering disclosure to push back the expected listing date of 51,660,308 new common shares (par/issue price US$0.33, issued via third-party allotment converting rehabilitation debt to equity) from July 15, 2026 to July 22, 2026, due to processing delays with the Korea Securities Depository.
Capital raise · Jul 8 - [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$19.9M, about 15.6% of its market value.
Capital raise · Jun 16 - [Amended] Material event report (rights offering)Capital raise · Jun 16
- [Amended] Material event report (rights offering)
Union Korea Pharm updated the terms of a private placement (third-party allotment) to raise US$19.7M, about 15.6% of its market value.
Capital raise · Jun 9 - [Amended] Material event report (rights offering)Capital raise · Jun 9
- Securities issuance results (voluntary) (third-party placement)Capital raise · May 27
- Change of largest shareholderOwnership change · May 27
- Change of largest shareholderOwnership change · May 19
- Securities issuance results (voluntary)Capital raise · May 19
- Material event report (rights offering)
Union Korea Pharm disclosed a private placement (third-party allotment) to raise US$19.9M, about 15.6% of its market value.
Capital raise · May 19 - Material event report (rights offering)Capital raise · May 19